fcmedicineФундаментальная и клиническая медицинаFundamental and Clinical Medicine2500-07642542-0941КемГМУ10.23946/2500-0764-2020-5-4-117-125fcmedicine-345Research ArticleОБЗОРНЫЕ СТАТЬИREVIEW ARTICLESРенальная денервация. новая жизнь технологииенальная денервация. новая жизнь технологииRenal denervation: a new life of the technologyhttps://orcid.org/0000-0001-5011-0070ЧичковаТ. Ю.ChichkovaT. Y.

Чичкова Татьяна Юрьевна, кандидат медицинских наук, научный сотрудник лаборатории нарушения ритма сердца и электрокардиостимуляции

650002, Россия, г. Кемерово, Сосновый бульвар, д. 6

Tatiana Y. Chichkova, MD, PhD, Research Fellow, Laboratory for Arrhythmia Research and Cardiac Stimulation

6, Sosnovy Boulevard, Kemerovo, 650002

chi4cova@ya.ruhttps://orcid.org/0000-0002-8277-5584МамчурС Е.MamchurS. E.

Мамчур Сергей Евгеньевич, доктор медицинских наук, заведующий лабораторией нарушения ритма сердца и электрокардиостимуляции

650002, Россия, г. Кемерово, Сосновый бульвар, д. 6

Sergey E. Mamchur, MD, DSc, Laboratory for Arrhythmia Research and Cardiac Stimulation

6, Sosnovy Boulevard, Kemerovo, 650002

https://orcid.org/0000-0002-0598-1675РомановаМ. П.RomanovaM. P.

Романова Мария Петровна, младший научный сотрудник лаборатории нарушения ритма сердца и электрокардиостимуляции

650002, Россия, г. Кемерово, Сосновый бульвар, д. 6

Maria P. Romanova, MD, Junior Researcher, Laboratory for Arrhythmia Research and Cardiac Stimulation

6, Sosnovy Boulevard, Kemerovo, 650002

https://orcid.org/0000-0002-1933-7768ХоменкоЕ. А.KhomenkoE. A.

Хоменко Егор Александрович, кандидат медицинских наук, научный сотрудник лаборатории нарушения ритма сердца и электрокардиостимуляции

650002, Россия, г. Кемерово, Сосновый бульвар, д. 6

Egor A. Khomenko, MD, PhD, Research Fellow, Laboratory for Arrhythmia Research and Cardiac Stimulation

6, Sosnovy Boulevard, Kemerovo, 650002

ФГБНУ«Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»РоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation20202512202054117125Copyright © Чичкова Т.Ю., Мамчур С.Е., Романова М.П., Хоменко Е.А., 20202020Чичкова Т.Ю., Мамчур С.Е., Романова М.П., Хоменко Е.А.Chichkova T.Y., Mamchur S.E., Romanova M.P., Khomenko E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://fcm.kemsmu.ru/jour/article/view/345

Ренальная денервация (РД) – метод модуляции тонуса автономной нервной системы, разработанный для лечения резистентных форм артериальной гипертензии (АГ). Первые сообщения о высокой эффективности РД дали толчок к развитию технологии. Однако после публикации данных первого рандомизированного контролируемого клинического исследования (РКИ) Symplicity HTN-3, не показавшего преимуществ технологии, интерес к ней значительно угас. Разработка и публикации данных новых РКИ с усовершенствованным дизайном SPYRAL HTNOFF MED и SPYRAL HTN-ON MED позволили методу возродиться. В исследованиях было показано, что РД приводит к снижению как офисных, так и среднесуточных значений АД, эффективна у пациентов с неконтролируемой АГ даже в условиях отсутствия медикаментозной терапии в сравнении с ложной (sham) процедурой. Кроме того, эффект вмешательства сохраняется в течение 24 часов, характеризуется положительным влиянием на параметры суточного профиля АД и не зависит от приверженности к лечению. В настоящем обзоре представлены данные об эффективности и безопасности технологии, отражены ее органопротективные эффекты, а также обсуждается вопрос о преимуществах РД у различных групп пациентов.

Renal denervation (RDN) is a method of the sympathetic nervous system modulation which has been specifically developed for the treatment of resistant hypertension. Initial reports demonstrating high efficiency of RDN in such patients propelled the development of the technology, yet a specific randomised controlled trial Symplicity HTN-3 did not show its benefits. Data from the subsequent RCTs SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED have shown that RDN reduces both office and daily blood pressure, does not depend on the patient adherence, and is efficient in patients with uncontrolled hypertension even in the absence of drug therapy. This review summarises the data on the efficacy and safety of the technology, its organoprotective effects, and also discusses the benefits of the RDN in different patient groups.

резистентная артериальная гипертензияренальная денервацияresistant arterial hypertensionrenal denervationReferencesde Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY Investigators. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension. 2017;69(4):678-684. https://doi.org/10.1161/HYPERTENSIONAHA.116.08818de Jager RL, de Beus E, Beeftink MM, Sanders MF, Vonken EJ, Voskuil M, van Maarseveen EM, Bots ML, Blankestijn PJ; SYMPATHY Investigators. Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial. Hypertension. 2017;69(4):678-684. https://doi.org/10.1161/HYPERTENSIONAHA.116.08818Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-1909. https:// doi.org/10.1016/S0140-6736(10)62039-9Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-1909. https:// doi.org/10.1016/S0140-6736(10)62039-9Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flackn JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. https://doi.org/ 10.1056/ NEJMoa1402670.Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flackn JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. https://doi.org/ 10.1056/ NEJMoa1402670.Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G; SYMPLICITY HTN-3 Investigators. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9(10):769-779. https://doi.org/10.1016/j. jash.2015.08.001Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G; SYMPLICITY HTN-3 Investigators. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015;9(10):769-779. https://doi.org/10.1016/j. jash.2015.08.001Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219- 227. https://doi.org/10.1093/eurheartj/ehu441Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219- 227. https://doi.org/10.1093/eurheartj/ehu441Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635-643. https://doi.org/ 10.1016/j.jacc.2014.03.059.Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635-643. https://doi.org/ 10.1016/j.jacc.2014.03.059.Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, SchulzJander D, Linz D, Davies J, Kandzari DE, Whitbourn R, Böhm M, Melder RJ. Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. J Am Coll Cardiol. 2015;66(16):1766-1775. https://doi.org/10.1016/j.jacc.2015.08.018Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, SchulzJander D, Linz D, Davies J, Kandzari DE, Whitbourn R, Böhm M, Melder RJ. Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. J Am Coll Cardiol. 2015;66(16):1766-1775. https://doi.org/10.1016/j.jacc.2015.08.018Hutchinson BD, Keane D, Dodd JD. Renal sympathetic denervation: MDCT evaluation of the renal arteries. AJR Am J Roentgenol. 2013;201(2):W342-346. https://doi. org/10.2214/AJR.12.8560Hutchinson BD, Keane D, Dodd JD. Renal sympathetic denervation: MDCT evaluation of the renal arteries. AJR Am J Roentgenol. 2013;201(2):W342-346. https://doi. org/10.2214/AJR.12.8560Fengler K, Rommel KP, Blazek S, Besler C, Hartung P, von Roeder M, Petzold M, Winkler S, Höllriegel R, Desch S, Thiele H, Lurz P. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUNDHTN). Circulation. 2019;139(5):590-00.https://doi. org/10.1161/CIRCULATIONAHA.118.037654.Fengler K, Rommel KP, Blazek S, Besler C, Hartung P, von Roeder M, Petzold M, Winkler S, Höllriegel R, Desch S, Thiele H, Lurz P. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUNDHTN). Circulation. 2019;139(5):590-00.https://doi. org/10.1161/CIRCULATIONAHA.118.037654.Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, Azizi M, Diaz-Cartelle J, Cohen-Mazor M. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention. 2015;10(10):1213-20. https://doi.org/ 10.4244/EIJY14M12_01Sievert H, Schofer J, Ormiston J, Hoppe UC, Meredith IT, Walters DL, Azizi M, Diaz-Cartelle J, Cohen-Mazor M. Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention. 2015;10(10):1213-20. https://doi.org/ 10.4244/EIJY14M12_01Чичкова Т.Ю., Мамчур С.Е., Романова М.П., Хоменко Е.А. Влияние ренальной денервации на показатели суточного профиля артериального давления у пациентов с резистентной гипертензией. Фундаментальная и клиническая медицина. 2019;4(4):78-88. https://doi. org/10.23946/2500-0764-2019-4-4-78-88Chichkova TYu, Mamchur SE, Romanova MP, Khomenko EA. Impact of renal denervation on 24-hour blood pressure pattern in patients with resistant hypertension. Fundamental and Clinical Medicine. 2019;4(4):78-88. (In Russ.).https://doi. org/10.23946/2500-0764-2019-4-4-78-88Karanasos A, Van Mieghem N, Bergmann MW, Hartman E, Ligthart J, van der Heide E, Heeger CH, Ouhlous M, Zijlstra F, Regar E, Daemen J. Multimodality Intra-Arterial Imaging Assessment of the Vascular Trauma Induced by BalloonBased and Nonballoon-Based Renal Denervation Systems. Circ Cardiovasc Interv. 2015;8(7):e002474. https://doi. org/10.1161/CIRCINTERVENTIONS.115.002474Karanasos A, Van Mieghem N, Bergmann MW, Hartman E, Ligthart J, van der Heide E, Heeger CH, Ouhlous M, Zijlstra F, Regar E, Daemen J. Multimodality Intra-Arterial Imaging Assessment of the Vascular Trauma Induced by BalloonBased and Nonballoon-Based Renal Denervation Systems. Circ Cardiovasc Interv. 2015;8(7):e002474. https://doi. org/10.1161/CIRCINTERVENTIONS.115.002474Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K; SPYRAL HTNON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-2355. https://doi.org/DOI: 10.1016/ S0140-6736(18)30951-6Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K; SPYRAL HTNON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-2355. https://doi.org/DOI: 10.1016/ S0140-6736(18)30951-6Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M; SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): arandomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-2170. https://doi.org/10.1016/ S0140-6736(17)32281-XTownsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M; SPYRAL HTN-OFF MED trial investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): arandomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-2170. https://doi.org/10.1016/ S0140-6736(17)32281-XBöhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D'Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTNOFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-1451. https:// doi.org/10.1016/S0140-6736(20)30554-7Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C, Lee DP, Ma A, Ewen S, Cohen DL, Wilensky R, Devireddy CM, Lea J, Schmid A, Weil J, Agdirlioglu T, Reedus D, Jefferson BK, Reyes D, D'Souza R, Sharp ASP, Sharif F, Fahy M, DeBruin V, Cohen SA, Brar S, Townsend RR; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTNOFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-1451. https:// doi.org/10.1016/S0140-6736(20)30554-7Mauri L, Kario K, Basile J, Daemen J, Davies J, Kirtane AJ, Mahfoud F, Schmieder RE, Weber M, Nanto S, Azizi M. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195:115-129. https://doi.org/10.1016/j. ahj.2017.09.006Mauri L, Kario K, Basile J, Daemen J, Davies J, Kirtane AJ, Mahfoud F, Schmieder RE, Weber M, Nanto S, Azizi M. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195:115-129. https://doi.org/10.1016/j. ahj.2017.09.006Wang JG, Kario K, Park JB, Chen CH. Morning blood pressure monitoring in the management of hypertension. J Hypertens. 2017;35(8):1554-1563. https://doi.org/ doi: 10.1097/HJH.0000000000001379. PMID: 28379890.Wang JG, Kario K, Park JB, Chen CH. Morning blood pressure monitoring in the management of hypertension. J Hypertens. 2017;35(8):1554-1563. https://doi.org/ doi: 10.1097/HJH.0000000000001379. PMID: 28379890.Li Y, Thijs L, Hansen TW, Kikuya M, Boggia J, Richart T, Metoki H, Ohkubo T, Torp-Pedersen C, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Sandoya E, Kawecka-Jaszcz K, Ibsen H, Imai Y, Wang J, Staessen JA. International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010;55(4):1040-1048. https:// doi.org/10.1161/HYPERTENSIONAHA.109.137273Li Y, Thijs L, Hansen TW, Kikuya M, Boggia J, Richart T, Metoki H, Ohkubo T, Torp-Pedersen C, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Sandoya E, Kawecka-Jaszcz K, Ibsen H, Imai Y, Wang J, Staessen JA. International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes Investigators. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension. 2010;55(4):1040-1048. https:// doi.org/10.1161/HYPERTENSIONAHA.109.137273Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, Shimada K. Morning Home Blood Pressure Is a Strong Predictor of Coronary Artery Disease: The HONEST Study. J Am Coll Cardiol. 2016;67(13):1519-1527. https://doi. org/10.1016/j.jacc.2016.01.037Kario K, Saito I, Kushiro T, Teramukai S, Tomono Y, Okuda Y, Shimada K. Morning Home Blood Pressure Is a Strong Predictor of Coronary Artery Disease: The HONEST Study. J Am Coll Cardiol. 2016;67(13):1519-1527. https://doi. org/10.1016/j.jacc.2016.01.037Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, Schlaich M, Williams B, Fahy M, Mancia G. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474- 3482. https://doi.org/10.1093/eurheartj/ehz118Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, Schlaich M, Williams B, Fahy M, Mancia G. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40(42):3474- 3482. https://doi.org/10.1093/eurheartj/ehz118Kordalis A, Tsiachris D, Pietri P, Tsioufis C, Stefanadis C. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. J Hypertens. 2018;36(8):1614-1621. https://doi.org/10.1097/ HJH.0000000000001798Kordalis A, Tsiachris D, Pietri P, Tsioufis C, Stefanadis C. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. J Hypertens. 2018;36(8):1614-1621. https://doi.org/10.1097/ HJH.0000000000001798Sharp TE, Polhemus DJ, Li Z, Spaletra P, Jenkins JS, Reilly JP, White CJ, Kapusta DR, Lefer DJ, Goodchild TT. Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System. J Am Coll Cardiol. 2018;72(21):2609-2621. https://doi.org/10.1016/j. jacc.2018.08.2186Sharp TE, Polhemus DJ, Li Z, Spaletra P, Jenkins JS, Reilly JP, White CJ, Kapusta DR, Lefer DJ, Goodchild TT. Renal Denervation Prevents Heart Failure Progression Via Inhibition of the Renin-Angiotensin System. J Am Coll Cardiol. 2018;72(21):2609-2621. https://doi.org/10.1016/j. jacc.2018.08.2186Fukuta H, Goto T, Wakami K, Ohte N. Effects of catheterbased renal denervation on heart failure with reduced ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2017;22(6):657-664. https://doi.org/10.1007/s10741- 017-9629-0Fukuta H, Goto T, Wakami K, Ohte N. Effects of catheterbased renal denervation on heart failure with reduced ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2017;22(6):657-664. https://doi.org/10.1007/s10741- 017-9629-0Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E, Polyakov K, Ptaszynski P, Keweloh B, Yao CJ, Pokushalov EA, Romanov AB. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA. 2020;323(3):248-255. https://doi.org/10.1001/jama.2019.21187Steinberg JS, Shabanov V, Ponomarev D, Losik D, Ivanickiy E, Kropotkin E, Polyakov K, Ptaszynski P, Keweloh B, Yao CJ, Pokushalov EA, Romanov AB. Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial. JAMA. 2020;323(3):248-255. https://doi.org/10.1001/jama.2019.21187Rosa J, Widimský P, Toušek P, Petrák O, Čurila K, Waldauf P, Bednář F, Zelinka T, Holaj R, Štrauch B, Šomlóová Z, Táborský M, Václavík J, Kociánová E, Branny M, Nykl I, Jiravský O, Widimský J Jr. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65(2):407-413. https://doi.org/10.1161/ HYPERTENSIONAHA.114.04019Rosa J, Widimský P, Toušek P, Petrák O, Čurila K, Waldauf P, Bednář F, Zelinka T, Holaj R, Štrauch B, Šomlóová Z, Táborský M, Václavík J, Kociánová E, Branny M, Nykl I, Jiravský O, Widimský J Jr. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65(2):407-413. https://doi.org/10.1161/ HYPERTENSIONAHA.114.04019Oliveras A, Armario P, Clarà A, Sans-Atxer L, Vázquez S, Pascual J, De la Sierra A. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016;34(9):1863-1871. https://doi. org/10.1097/HJH.0000000000001025Oliveras A, Armario P, Clarà A, Sans-Atxer L, Vázquez S, Pascual J, De la Sierra A. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016;34(9):1863-1871. https://doi. org/10.1097/HJH.0000000000001025de Jong MR, Adiyaman A, Gal P, Smit JJ, Delnoy PP, Heeg JE, van Hasselt BA, Lau EO, Persu A, Staessen JA, Ramdat Misier AR, Steinberg JS, Elvan A. Renal Nerve StimulationInduced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation. Hypertension. 2016 Sep;68(3):707-714. https://doi.org/10.1161/ HYPERTENSIONAHA.116.07492de Jong MR, Adiyaman A, Gal P, Smit JJ, Delnoy PP, Heeg JE, van Hasselt BA, Lau EO, Persu A, Staessen JA, Ramdat Misier AR, Steinberg JS, Elvan A. Renal Nerve StimulationInduced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation. Hypertension. 2016 Sep;68(3):707-714. https://doi.org/10.1161/ HYPERTENSIONAHA.116.07492Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation following catheter-based radio-frequency renal denervation. Exp Physiol. 2015;100(5):485-490. https://doi.org/10.1113/ expphysiol.2014.079871Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation following catheter-based radio-frequency renal denervation. Exp Physiol. 2015;100(5):485-490. https://doi.org/10.1113/ expphysiol.2014.079871SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939Schmieder RE, Högerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12):1331-1342. https://doi.org/10.1007/s00392- 019-01468-0Schmieder RE, Högerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12):1331-1342. https://doi.org/10.1007/s00392- 019-01468-0Чичкова Т.Ю., Мамчур С.Е., Хоменко Е.А., Романова М.П., Коков А.Н., Мамчур И.Н. Эффективность и безопасность многополюсной биполярной ренальной денервации и значение стимуляции почечных нервов для прогнозирования результатов вмешательства. Комплексные проблемы сердечно-сосудистых заболеваний. 2017;6(4):89-94. https://doi.org/10.17802/2306- 1278-2017-6-4-89-94Chichkova TY, Mamchur SE, Khomenko EA, Romanova MP, Kokov AN, Mamchur IN. Efficiency and safety of bipolar renal denervation and the role of renal nerves stimulation as a procedure results predictor. Kompleksnye problemy serdechno-sosudistykh zabolevaniy. 2017;6(4):89-94. (In Russ.). https://doi.org/10.17802/2306- 1278-2017-6-4-89-94

The authors declare that there are no conflicts of interest present.